DK3351240T3 - Formuleringer af 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion - Google Patents

Formuleringer af 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion Download PDF

Info

Publication number
DK3351240T3
DK3351240T3 DK18160247.5T DK18160247T DK3351240T3 DK 3351240 T3 DK3351240 T3 DK 3351240T3 DK 18160247 T DK18160247 T DK 18160247T DK 3351240 T3 DK3351240 T3 DK 3351240T3
Authority
DK
Denmark
Prior art keywords
dioxopiperidin
isoindolin
dion
formulations
amino
Prior art date
Application number
DK18160247.5T
Other languages
English (en)
Inventor
Anthony Tutino
Michael T Kelly
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42635489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3351240(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Application granted granted Critical
Publication of DK3351240T3 publication Critical patent/DK3351240T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DK18160247.5T 2009-05-19 2010-05-19 Formuleringer af 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion DK3351240T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17967809P 2009-05-19 2009-05-19
EP17151178.5A EP3199149A1 (en) 2009-05-19 2010-05-19 Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione

Publications (1)

Publication Number Publication Date
DK3351240T3 true DK3351240T3 (da) 2019-06-17

Family

ID=42635489

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18160247.5T DK3351240T3 (da) 2009-05-19 2010-05-19 Formuleringer af 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion
DK10720107.1T DK2391355T3 (da) 2009-05-19 2010-05-19 Formuleringer af 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10720107.1T DK2391355T3 (da) 2009-05-19 2010-05-19 Formuleringer af 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion

Country Status (34)

Country Link
US (6) US8828427B2 (da)
EP (3) EP2391355B1 (da)
JP (1) JP5752677B2 (da)
KR (1) KR101381060B1 (da)
CN (3) CN106176662A (da)
AU (1) AU2010249615B2 (da)
BR (1) BRPI1007855B1 (da)
CA (1) CA2752550C (da)
CL (1) CL2011001969A1 (da)
CO (1) CO6430422A2 (da)
CR (1) CR20110435A (da)
CY (2) CY1118632T1 (da)
DK (2) DK3351240T3 (da)
EC (1) ECSP11011317A (da)
ES (2) ES2615511T3 (da)
HR (2) HRP20170179T1 (da)
HU (2) HUE033115T2 (da)
IL (2) IL214644A (da)
LT (2) LT3351240T (da)
MX (2) MX342330B (da)
NI (1) NI201100158A (da)
NZ (1) NZ594557A (da)
PE (1) PE20120654A1 (da)
PH (1) PH12015501523A1 (da)
PL (2) PL3351240T3 (da)
PT (2) PT3351240T (da)
RU (1) RU2479307C1 (da)
SG (1) SG174137A1 (da)
SI (2) SI3351240T1 (da)
SM (1) SMT201700097B (da)
TR (1) TR201905423T4 (da)
UA (1) UA102582C2 (da)
WO (1) WO2010135396A2 (da)
ZA (1) ZA201105962B (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
EP2391355B1 (en) 2009-05-19 2017-01-18 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
WO2014160698A1 (en) 2013-03-26 2014-10-02 Celgene Corporation SOLID FORMS COMPRISING 4-AMINO-I-β-D-RIBOFURANOSYL-1,3,5-TRIAZIN-2(1H)-ONE AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
KR20150136078A (ko) * 2013-04-02 2015-12-04 셀진 코포레이션 중추신경계 암의 치료 및 관리를 위한 4-아미노-2-(2,6-디옥소-피페리딘-3-일)-이소인돌린-1,3-디온을 사용한 방법 및 조성물
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
NZ631364A (en) * 2013-08-08 2017-09-29 Array Biopharma Inc Filanesib combined with pomalidomide displays enhanced anti-tumor activity
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
KR20170042598A (ko) 2014-08-22 2017-04-19 셀진 코포레이션 항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법
CN104523692A (zh) * 2014-12-16 2015-04-22 南京艾德凯腾生物医药有限责任公司 一种泊马度胺复合物及其制备方法
RS62352B1 (sr) 2015-06-29 2021-10-29 Bristol Myers Squibb Co Imunoterapijski režimi doziranja koji obuhvataju pomalidomid i anti-cs1 antitelo za lečenje kancera
CN105213392A (zh) * 2015-09-29 2016-01-06 浙江大学 泊马度胺在制备减轻多发性硬化症的药物中的应用
WO2018013689A1 (en) 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof
WO2018013693A1 (en) 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof
RU2019105711A (ru) * 2016-08-02 2020-09-04 Синтон Б.В. Фармацевтическая композиция, содержащая помалидомид
WO2018150435A1 (en) * 2017-02-18 2018-08-23 Natco Pharma Limited Pharmaceutical compositions of pomalidomide
US10093647B1 (en) 2017-05-26 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
JP2020533383A (ja) 2017-09-14 2020-11-19 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌の組合せ治療
US10093649B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
US10093648B1 (en) * 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
CN111372585A (zh) 2017-11-16 2020-07-03 C4医药公司 用于靶蛋白降解的降解剂和降解决定子
CN107982216A (zh) * 2017-12-08 2018-05-04 佛山市弘泰药物研发有限公司 一种泊马度胺自微乳制剂及其制备方法
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
KR20210018199A (ko) 2018-03-26 2021-02-17 씨4 테라퓨틱스, 인코포레이티드 이카로스의 분해를 위한 세레블론 결합제
EP3545949A1 (en) * 2018-03-29 2019-10-02 Midas Pharma GmbH Oral dosage forms comprising pomalidomide crystalline form a
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
WO2020051235A1 (en) 2018-09-04 2020-03-12 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN DEGRADATION
CN113557235A (zh) 2019-03-06 2021-10-26 C4医药公司 用于药物治疗的杂环化合物
EA039874B1 (ru) * 2019-06-06 2022-03-22 Общество С Ограниченной Ответственностью "Технология Лекарств" Композиция помалидомида для лечения заболеваний, ассоциированных с фактором некроза опухоли (фно)
BR112022020897A2 (pt) 2020-04-15 2022-11-29 Tecnimede Soc Tecnico Medicinal Sa Forma de dosagem oral sólida compreendendo pomalidomida.
EP3900701A1 (en) 2020-04-22 2021-10-27 Lotus Pharmaceutical Co., Ltd. Composition of pomalidomide for oral dosage form
WO2023062647A1 (en) * 2021-10-12 2023-04-20 Reliance Life Sciences Pvt.Ltd. Pomalidomide formulation
EP4233849A1 (en) 2022-02-25 2023-08-30 KRKA, d.d., Novo mesto Pharmaceutical composition comprising pomalidomide

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US555939A (en) * 1896-03-10 Device for opening sealed packages
US3145146A (en) 1961-10-31 1964-08-18 Warner Lambert Pharmaceutical Modified mannitol for pharmaceutical tablets
US3980766A (en) 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
JPS601128A (ja) 1983-06-15 1985-01-07 Shionogi & Co Ltd 作用持続型セフアクロル製剤
US4551177A (en) 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
JPS6396126A (ja) 1986-10-13 1988-04-27 Taisho Pharmaceut Co Ltd 安定化組成物
US5974203A (en) 1988-04-11 1999-10-26 Canon Kabushiki Kaisha Pattern recognition communication apparatus for transmitting and receiving image data
AU1531492A (en) 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US5594637A (en) 1993-05-26 1997-01-14 Base Ten Systems, Inc. System and method for assessing medical risk
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
WO1995003807A1 (en) 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
BR9509357A (pt) 1994-10-28 1997-12-30 Advanced Health Med E Systems Sistema de gerenciamento de prescrições implementado em computador prescrição combinação formada por uma instalação de computador central em um sistema de gerenciamento de prescrições embalagem dispositivo de indicação de dosagem e sistema de especifica o de produtos para o uso profissional
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5619991A (en) 1995-04-26 1997-04-15 Lucent Technologies Inc. Delivery of medical services using electronic data communications
IT1274549B (it) 1995-05-23 1997-07-17 Indena Spa Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
US5731325A (en) 1995-06-06 1998-03-24 Andrulis Pharmaceuticals Corp. Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
JPH0977669A (ja) 1995-09-19 1997-03-25 Takeda Chem Ind Ltd ビタミンｂ群顆粒品の組成物およびその製造方法
US5832449A (en) 1995-11-13 1998-11-03 Cunningham; David W. Method and system for dispensing, tracking and managing pharmaceutical trial products
US6063026A (en) 1995-12-07 2000-05-16 Carbon Based Corporation Medical diagnostic analysis system
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
PT925294E (pt) 1996-07-24 2003-04-30 Celgene Corp 2-(2,6-dioxopiperidin-3-il)-ftalimidas e -1-oxoisoindolinas substituidas e metodo de reducao dos niveis de tnf-alfa
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US5924074A (en) 1996-09-27 1999-07-13 Azron Incorporated Electronic medical records system
US6131090A (en) 1997-03-04 2000-10-10 Pitney Bowes Inc. Method and system for providing controlled access to information stored on a portable recording medium
WO1999010829A1 (en) 1997-08-22 1999-03-04 Deka Products Limited Partnership Health care system and method for physician order entry
US6015803A (en) 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US6001368A (en) 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
CA2350304A1 (en) 1998-11-10 2000-05-18 Teva Pharmaceutical Industries, Ltd. Dispersible compositions containing l-dopa ethyl ester
GB9901819D0 (en) 1999-01-27 1999-03-17 Scherer Corp R P Pharmaceutical compositions
GB9904585D0 (en) 1999-02-26 1999-04-21 Gemini Research Limited Clinical and diagnostic database
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US6202923B1 (en) 1999-08-23 2001-03-20 Innovation Associates, Inc. Automated pharmacy
ES2367007T3 (es) 1999-11-24 2011-10-27 Sugen, Inc. Derivados de indolinona ionizables y su uso como ligandos de ptk.
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
AU2002253795B2 (en) 2000-11-30 2007-02-01 The Children's Medical Center Corporation Synthesis of 4-Amino-Thalidomide enantiomers
US20020128228A1 (en) 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer
JP4334869B2 (ja) 2000-12-01 2009-09-30 協和発酵キリン株式会社 溶解性または経口吸収性の改善された組成物
US20040190609A1 (en) 2001-11-09 2004-09-30 Yasuhiko Watanabe Moving picture coding method and apparatus
JP4027693B2 (ja) 2002-03-20 2007-12-26 トリニティ工業株式会社 塗料送給装置及びバルブユニット
WO2003086373A1 (en) * 2002-04-12 2003-10-23 Celgene Corporation Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US7230012B2 (en) 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
US20040191298A1 (en) 2003-03-26 2004-09-30 Fredrik Nicklasson New formulations and use thereof
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO2005051350A2 (en) 2003-10-28 2005-06-09 Torrent Pharmaceuticals Limited Water dispersible tablet
US20050100529A1 (en) 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
JP5089170B2 (ja) 2003-12-02 2012-12-05 セルジーン コーポレイション 異常ヘモグロビン症及び貧血症の治療及び管理のための方法及び組成物
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
GB0400993D0 (en) 2004-01-16 2004-02-18 Norton Healthcare Ltd Stable gabapentin compositions
MXPA06010699A (es) 2004-03-22 2006-12-15 Celgene Corp Metodos de usos y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades o alteraciones de la piel.
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
US20050239842A1 (en) 2004-04-23 2005-10-27 Zeldis Jerome B Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
MX2007005570A (es) 2004-11-12 2007-07-09 Celgene Corp Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y manejo de padecimientos parasiticos.
MX2007006063A (es) * 2004-11-23 2007-07-11 Celgene Corp Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de lesion al sistema nervioso central.
BRPI0607791A2 (pt) 2005-03-15 2010-03-23 Lupin Ltd composiÇÕes farmacÊuticas de amlodipina e benazepril
KR101435199B1 (ko) 2005-05-18 2014-08-28 다이닛본 스미토모 세이야꾸 가부시끼가이샤 드록시도파를 함유하는 안정한 정제
US8729085B2 (en) 2005-05-26 2014-05-20 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical composition
JP2007028086A (ja) 2005-07-14 2007-02-01 Funai Electric Co Ltd リモコン装置
US8715677B2 (en) 2005-09-01 2014-05-06 Celgene Corporation Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
ZA200805795B (en) * 2005-12-29 2009-10-28 Celgene Corp Methods for treating cutaneous lupus using aminoisoindoline compounds
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
JP2011510983A (ja) 2008-01-29 2011-04-07 セルジーン コーポレイション Ｃｄ５９のレベルを調節するための、免疫調節化合物を使用する方法
EP2391355B1 (en) 2009-05-19 2017-01-18 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione

Also Published As

Publication number Publication date
HUE033115T2 (en) 2017-11-28
IL241949A (en) 2017-08-31
IL214644A0 (en) 2011-11-30
MX2011008554A (es) 2011-10-06
CA2752550C (en) 2014-07-15
PT2391355T (pt) 2017-02-21
EP3351240A1 (en) 2018-07-25
PL2391355T3 (pl) 2017-05-31
EP3351240B1 (en) 2019-04-10
PT3351240T (pt) 2019-06-21
US20110045064A1 (en) 2011-02-24
IL214644A (en) 2015-10-29
WO2010135396A2 (en) 2010-11-25
CN106176662A (zh) 2016-12-07
EP3199149A1 (en) 2017-08-02
US20210085665A1 (en) 2021-03-25
CO6430422A2 (es) 2012-04-30
BRPI1007855B1 (pt) 2020-03-10
IL241949A0 (en) 2015-11-30
US10555939B2 (en) 2020-02-11
EP2391355B1 (en) 2017-01-18
AU2010249615B2 (en) 2013-07-18
UA102582C2 (en) 2013-07-25
HUE043862T2 (hu) 2021-12-28
CN102333525A (zh) 2012-01-25
BRPI1007855A2 (pt) 2016-02-23
CY1122064T1 (el) 2020-11-25
JP2012526855A (ja) 2012-11-01
PE20120654A1 (es) 2012-05-31
SMT201700097B (it) 2017-03-08
WO2010135396A3 (en) 2011-09-15
US20180325885A1 (en) 2018-11-15
LT3351240T (lt) 2019-06-10
US20160206607A1 (en) 2016-07-21
US20140336223A1 (en) 2014-11-13
HRP20191094T1 (hr) 2019-09-20
US9993467B2 (en) 2018-06-12
NI201100158A (es) 2012-01-24
ZA201105962B (en) 2012-11-28
CN105640918A (zh) 2016-06-08
LT2391355T (lt) 2017-03-10
ES2615511T3 (es) 2017-06-07
SI3351240T1 (sl) 2019-08-30
KR101381060B1 (ko) 2014-04-11
NZ594557A (en) 2013-07-26
SI2391355T1 (sl) 2017-07-31
MX342330B (es) 2016-09-26
US8828427B2 (en) 2014-09-09
ES2728776T3 (es) 2019-10-28
KR20120014114A (ko) 2012-02-16
PL3351240T3 (pl) 2019-09-30
SG174137A1 (en) 2011-10-28
TR201905423T4 (tr) 2019-05-21
EP2391355A2 (en) 2011-12-07
PH12015501523A1 (en) 2015-09-21
JP5752677B2 (ja) 2015-07-22
HRP20170179T1 (hr) 2017-04-07
RU2011134499A (ru) 2013-02-27
CY1118632T1 (el) 2017-07-12
CA2752550A1 (en) 2010-11-25
CR20110435A (es) 2012-01-06
AU2010249615A1 (en) 2011-09-08
DK2391355T3 (da) 2017-02-27
CL2011001969A1 (es) 2012-07-20
US20200222382A1 (en) 2020-07-16
RU2479307C1 (ru) 2013-04-20
ECSP11011317A (es) 2011-10-31

Similar Documents

Publication Publication Date Title
DK3351240T3 (da) Formuleringer af 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion
DK2498756T3 (da) Tabletformuleringer af neratinibmaleat
DK3721904T3 (da) Formuleringer af t1h-antistof
DK3078664T3 (da) Antiparasitiske dihydroazol-sammensætninger
FR2929950B1 (fr) Compositions de silicone chargees
BRPI0908785A2 (pt) Formulações herbicida
UY33161A (es) Composiciones plaguicidas
DK3158991T3 (da) Formuleringer af bendamustin
BRPI0814188A2 (pt) Formulações
DK2442771T3 (da) Silikone-arbehandlingspræparat
BRPI0918249A2 (pt) prótese
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener
BRPI1010690A2 (pt) composições
FI8622U1 (sv) Stolpsko
DK2429902T3 (da) Batchopsamler
DK2233133T3 (da) Stabile rosuvastatinsammensætninger
BRPI1013462A2 (pt) Formulações herbicidas
DE112010002033B8 (de) Biohydrofuel-Zusammensetzungen
DK2407155T3 (da) Formuleringer af inecalcitol
BR112012002281A2 (pt) composicoes poliofinicas
BR112012002292A2 (pt) composições poliofínicas
UY33138A (es) Formulaciones liquidas
BRPI1011570A2 (pt) composições
IT1397722B1 (it) Struttura di bottone rimovibile
CN300909518S (zh) 瓷片(人造石-伊丽莎白)